BioCryst posted Q2 GAAP net income of USD 78.4 million, swinging from profit of USD 5.09 million a year earlier.
Revenue climbed 34% year over year to USD 218.3 million, lifted by USD 158.2 million from ORLADEYO.
GAAP operating income rose to USD 98.5 million; non-GAAP operating income increased to USD 113.2 million.
Cash, cash equivalents, restricted cash and investments totaled USD 354 million at June 30.
Product and pipeline updates
ORLADEYO oral pellets began shipping the week of Aug. 3; enrollment finished in the ALPHA-ORBIT navenibart pivotal study with top-line data due Q3 2027.
BCRX•
